4//SEC Filing
ACURA PHARMACEUTICALS, INC 4
Accession 0001209191-14-015475
$ACURCIK 0000786947operating
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 8:10 PM ET
Size
21.4 KB
Accession
0001209191-14-015475
Insider Transaction Report
Form 4
CLAUDIUS LLC
10% Owner
Transactions
- Sale
Common Stock
2014-02-26$1.95/sh−5,000$9,773→ 11,471,078 total(indirect: See FN) - Sale
Common Stock
2014-02-27$2.04/sh−192,479$392,946→ 11,278,598 total(indirect: See FN) - Sale
Common Stock
2014-02-28$2.01/sh−147,480$295,756→ 11,131,118 total(indirect: See FN) - Sale
Common Stock
2014-02-26$1.95/sh−6,301$12,295→ 11,476,078 total(indirect: See FN)
GALEN PARTNERS INTERNATIONAL III L P
10% Owner
Transactions
- Sale
Common Stock
2014-02-26$1.95/sh−5,000$9,773→ 11,471,078 total(indirect: See FN) - Sale
Common Stock
2014-02-27$2.04/sh−192,479$392,946→ 11,278,598 total(indirect: See FN) - Sale
Common Stock
2014-02-26$1.95/sh−6,301$12,295→ 11,476,078 total(indirect: See FN) - Sale
Common Stock
2014-02-28$2.01/sh−147,480$295,756→ 11,131,118 total(indirect: See FN)
GALEN EMPLOYEE FUND III LP
10% Owner
Transactions
- Sale
Common Stock
2014-02-27$2.04/sh−192,479$392,946→ 11,278,598 total(indirect: See FN) - Sale
Common Stock
2014-02-28$2.01/sh−147,480$295,756→ 11,131,118 total(indirect: See FN) - Sale
Common Stock
2014-02-26$1.95/sh−6,301$12,295→ 11,476,078 total(indirect: See FN) - Sale
Common Stock
2014-02-26$1.95/sh−5,000$9,773→ 11,471,078 total(indirect: See FN)
Galen Management, LLC
10% Owner
Transactions
- Sale
Common Stock
2014-02-26$1.95/sh−5,000$9,773→ 11,471,078 total(indirect: See FN) - Sale
Common Stock
2014-02-28$2.01/sh−147,480$295,756→ 11,131,118 total(indirect: See FN) - Sale
Common Stock
2014-02-26$1.95/sh−6,301$12,295→ 11,476,078 total(indirect: See FN) - Sale
Common Stock
2014-02-27$2.04/sh−192,479$392,946→ 11,278,598 total(indirect: See FN)
GALEN PARTNERS III L P
10% Owner
Transactions
- Sale
Common Stock
2014-02-26$1.95/sh−6,301$12,295→ 11,476,078 total(indirect: See FN) - Sale
Common Stock
2014-02-26$1.95/sh−5,000$9,773→ 11,471,078 total(indirect: See FN) - Sale
Common Stock
2014-02-27$2.04/sh−192,479$392,946→ 11,278,598 total(indirect: See FN) - Sale
Common Stock
2014-02-28$2.01/sh−147,480$295,756→ 11,131,118 total(indirect: See FN)
Footnotes (11)
- [F1]The shares were sold as follows: 5,756 by Galen Partners III, L.P. ("Galen III"), 521 by Galen Partners International III, L.P. ("Galen International") and 24 by Galen Employee Fund III, L.P. ("Employee Fund").
- [F10]The shares were sold at prices between $2.00 and $2.07. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F11]The shares are held as follows: 10,171,959 by Galen III, 917,259 by Galen International and 41,903 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F2]The shares were sold at prices between $1.95 and $1.96. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The shares are held as follows: 10,487,099 by Galen III, 945,782 by Galen International and 43,198 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F4]The shares were sold as follows: 4,568 by Galen III, 413 by Galen International and 19 by Employee Fund.
- [F5]The shares are held as follows: 10,482,531 by Galen III, 945,369 by Galen International and 43,179 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F6]The shares were sold as follows: 175,841 by Galen III, 15,916 by Galen International and 722 by Employee Fund.
- [F7]The shares were sold at prices between $2.042 and $2.11. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F8]The shares are held as follows: 10,306,690 by Galen III, 929,453 by Galen International and 42,457 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F9]The shares were sold as follows: 134,731 by Galen III, 12,194 by Galen International and 554 by Employee Fund.
Documents
Issuer
ACURA PHARMACEUTICALS, INC
CIK 0000786947
Entity typeoperating
IncorporatedNY
Related Parties
1- filerCIK 0000786947
Filing Metadata
- Form type
- 4
- Filed
- Feb 27, 7:00 PM ET
- Accepted
- Feb 28, 8:10 PM ET
- Size
- 21.4 KB